🚀 VC round data is live in beta, check it out!
OncoZenge Valuation Multiples
Discover revenue and EBITDA valuation multiples for OncoZenge and similar public comparables like BioAtla, Addex Therapeutics, ODI Pharma, Gelteq and more.
OncoZenge Overview
About OncoZenge
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
Founded
2020
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$8M
OncoZenge Financials
OncoZenge reported last fiscal year revenue of $291K and negative EBITDA of ($2M).
In the same fiscal year, OncoZenge generated ($2M) in EBITDA losses and had net loss of ($2M).
OncoZenge P&L
In the most recent fiscal year, OncoZenge reported revenue of $291K and EBITDA of ($2M).
OncoZenge expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $291K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (592%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (593%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (598%) | XXX | XXX | XXX |
| Net Debt | — | — | $413K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
OncoZenge Stock Performance
OncoZenge has current market cap of $8M, and enterprise value of $8M.
Market Cap Evolution
OncoZenge's stock price is $0.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $8M | 0.3% | XXX | XXX | XXX | $-0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncoZenge Valuation Multiples
OncoZenge trades at 28.8x EV/Revenue multiple, and (4.9x) EV/EBITDA.
OncoZenge Financial Valuation Multiples
As of April 19, 2026, OncoZenge has market cap of $8M and EV of $8M.
Equity research analysts estimate OncoZenge's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OncoZenge has a P/E ratio of (4.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 28.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (4.9x) | XXX | XXX | XXX |
| P/E | — | XXX | (4.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OncoZenge Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
OncoZenge Margins & Growth Rates
OncoZenge's revenue in the last fiscal year grew by —.
OncoZenge's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
OncoZenge Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (592%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 414% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 693% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
OncoZenge Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OncoZenge | XXX | XXX | XXX | XXX | XXX | XXX |
| BioAtla | XXX | XXX | XXX | XXX | XXX | XXX |
| Addex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ODI Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| Spago Nanomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OncoZenge M&A Activity
OncoZenge acquired XXX companies to date.
Last acquisition by OncoZenge was on XXXXXXXX, XXXXX. OncoZenge acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by OncoZenge
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncoZenge Investment Activity
OncoZenge invested in XXX companies to date.
OncoZenge made its latest investment on XXXXXXXX, XXXXX. OncoZenge invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by OncoZenge
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OncoZenge
| When was OncoZenge founded? | OncoZenge was founded in 2020. |
| Where is OncoZenge headquartered? | OncoZenge is headquartered in Sweden. |
| How many employees does OncoZenge have? | As of today, OncoZenge has over 2 employees. |
| Is OncoZenge publicly listed? | Yes, OncoZenge is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of OncoZenge? | OncoZenge trades under ONCOZ ticker. |
| When did OncoZenge go public? | OncoZenge went public in 2021. |
| Who are competitors of OncoZenge? | OncoZenge main competitors are BioAtla, Addex Therapeutics, ODI Pharma, Gelteq. |
| What is the current market cap of OncoZenge? | OncoZenge's current market cap is $8M. |
| What is the current revenue of OncoZenge? | OncoZenge's last fiscal year revenue is $291K. |
| What is the current EV/Revenue multiple of OncoZenge? | Current revenue multiple of OncoZenge is 28.8x. |
| Is OncoZenge profitable? | No, OncoZenge is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.